Drug-resistant clinical Candida responded to 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in vitro via enhanced ROS release
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01645-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Zhiya Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Laboratory of Medical Mycology, Jining No. 1 People's Hospital, Jining, Shandong, China. Hauptthemen laut MEDLINE: Aminolevulinic Acid, Reactive Oxygen Species, Antifungal Agents, Photochemotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Plan of Jining, National Natural Science Foundation of China.
Abstract (Originalsprache)
Photodynamic therapy (PDT) has emerged as a potential strategy to combat drug-resistant fungal infections. This study aimed to evaluate the therapeutic efficacy of 5-aminolevulinic acid PDT (ALA-PDT) against drug-resistant Candida strains isolated from patients with candidiasis and to elucidate its underlying mechanisms. Drug-resistant strains were identified by their reduced antifungal susceptibility to azoles, micafungin, amphotericin B, and terbinafine. RNA sequencing (RNA-seq) was used to assess gene expression related to mycelial formation and fungal growth. Scanning electron microscopy (SEM) was employed to observe cell-wall morphology after ALA-PDT treatment. Biofilm formation and intracellular reactive oxygen species (ROS) levels were also measured to investigate the mechanism of ALA-PDT-mediated fungal killing. Candida albicans and Candida tropicalis accounted for over half, predominantly from male ICU patients aged over 40 years. Candida spp. strains exhibited resistance rates of approximately 69.38% to terbinafine, 40.8% to azole antifungals, and 16.3% to micafungin among 49 drug-resistant isolates. Treatment with 20% ALA-PDT effectively eradicated those azole-resistant C. albicans in vitro , increased fungal killing, and significantly increased intracellular ROS levels. SEM analysis revealed varying degrees of cell-wall disruption, and RNA-seq demonstrated downregulation of mycelia-related genes following ALA-PDT. ALA-PDT effectively inhibits drug-resistant Candida spp. growth by inducing ROS-mediated cell damage and suppressing mycelial gene expression. These findings highlight ALA-PDT as a promising therapeutic approach for refractory candidiasis and provide mechanistic insights into its antifungal activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Laboratory of Medical Mycology, Jining No. 1 People's Hospital, Jining, Shandong, China.
- Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, China.
- Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
- Department of Microbiology and Immunology, Georgetown University Medical Center, Washington, DC, USA.
- Department of Dermatology, Jining No. 1 People's Hospital, Jining, Shandong, China.
ORCID-Profile: Zhiya Yang, Dongmei Li, Dongmei Shi
Förderung
- Key Research and Development Plan of Jining
- National Natural Science Foundation of China
Zitieren
APA
Yang, Z., Zhang, Y., Li, D., Wang, S., Shi, R., & Shi, D. (2026). Drug-resistant clinical Candida responded to 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in vitro via enhanced ROS release. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01645-25
Vancouver
Yang Z, Zhang Y, Li D, Wang S, Shi R, Shi D. Drug-resistant clinical Candida responded to 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in vitro via enhanced ROS release. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01645-25
BibTeX
@article{Yang2026,
author = {Yang, Zhiya and Zhang, Yonghong and Li, Dongmei and Wang, Sisi and Shi, Ruoyu and Shi, Dongmei},
title = {Drug-resistant clinical Candida responded to 5-aminolevulinic acid photodynamic therapy (ALA-PDT) in vitro via enhanced ROS release},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01645-25}
}
EUVIMED